CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 73 enrolled
Drug / intervention
Tadalafil +1 moredrug
Likely dose
Tadalafil 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01444651
NCT01444651Phase 3Completed
CompareCT.gov

Phase 3 Randomized Trial of Tadalafil and Glycemic Traits

Thomas J. Wang, MD·interventional·Posted Oct 3, 2011·Updated Jan 30, 2017

In Brief

A Phase 3 clinical trial evaluating Tadalafil and Placebo for Cardiovascular Disease and 3 related conditions. Completed, enrolled 73 participants across 1 site.

Detailed Summary

The purpose of this study is to find out if tadalafil can help overweight and obese people metabolize blood sugar more efficiently. The investigators also want to find out if 20 mg/day of tadalafil for 3 months is safe to take without causing too many side effects. The investigators are plan to enroll 100 subjects at Massachusetts General Hospital (MGH).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCardiovascular Disease, Insulin Resistance, Glucose Intolerance, Obesity
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedOct 3, 2011
Enrollment StartAug 1, 2011
Primary CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 14.7 years ago

Interventions

Tadalafildrug

20 mg Tadalafil taken once a day for 3 months

Placebodrug

Placebo tablet taken by mouth once a day for 3 months